Quick Facts

• Primary Use: Management of blood sugar levels in adults with type 2 diabetes mellitus.
• Therapeutic Role: Used as an adjunct to diet and a structured exercise program.
• Main Benefit: Helps improve the body's response to insulin.

---

Glafornil XR is an oral medication that serves as an established therapeutic option for adults diagnosed with type 2 diabetes mellitus. It is used to help improve the body's glycemic control by working alongside dietary management and a structured physical activity program.

The core benefit of this medication is its ability to help maintain blood sugar (glucose) levels within a safe range. By influencing the body’s glucose processes, Glafornil XR aims to contribute to the overall management of the condition. Effective management of type 2 diabetes may help mitigate potential risks associated with consistently elevated blood glucose.

This medication may be used as the initial monotherapy or may be prescribed in combination with other therapeutic agents for diabetes management, as determined by a healthcare provider. Glafornil XR supports a comprehensive approach to managing this chronic condition, focusing on favorable blood sugar outcomes.

Glafornil XR (metformin extended-release) is indicated for use in adults with Type 2 Diabetes Mellitus. The official regulatory labeling strictly defines several populations who must not use the medicine, who require restricted use, or for whom use is not established.

Contraindicated Populations

Classification	Regulatory Rule
Severe Renal Impairment	eGFR below 30 mL/min/1.73 m^2
Metabolic State	Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Allergy	Known hypersensitivity to metformin hydrochloride

Restricted and Non-Established Use

Renal Function: Initiation is not recommended if eGFR is between 30 and 45 mL/min/1.73 m^2. If eGFR later falls below 45 mL/min/1.73 m^2, the benefit/risk of continuing therapy must be assessed. The medicine is also typically discontinued temporarily for iodinated contrast imaging procedures in certain at-risk patients.

Hepatic Function: Use must be avoided in patients with clinical or laboratory evidence of hepatic impairment.

Age Groups: Safety and effectiveness have not been established for the extended-release formulation in pediatric patients under 18 years of age. Older adults require more frequent assessment of renal function.

Interactions with other medicines and products

Glafornil XR, which contains metformin, has officially documented interactions primarily related to the risk of drug accumulation and enhanced pharmacological effects. The official regulatory profile identifies specific drug classes and substances that necessitate careful consideration or temporary discontinuation.

Official Interaction Statements

• Exposure-Modifying Drugs: Co-administration with certain medications that reduce metformin clearance—such as ranolazine, vandetanib, dolutegravir, and cimetidine—may increase the accumulation of metformin. The benefits and risks of continued co-administration must be considered.
• Carbonic Anhydrase Inhibitors: The use of these medicines, including topiramate, may increase the risk of lactic acidosis. More frequent monitoring may be required during concomitant use.
• Glycemic Effects: When used with other glucose-lowering agents, such as insulin or insulin secretagogues, the risk of hypoglycemia is increased.
• Alcohol: Excessive alcohol intake can potentiate the effect of metformin on lactate metabolism; patients are warned against this combination.
• Iodinated Contrast Procedures: Metformin must be discontinued at the time of, or prior to, an iodinated contrast imaging procedure in patients with an estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min/1.73 m^2; in patients with a history of heart failure, liver disease, or alcoholism; or in patients receiving intra-arterial contrast. Resumption is based on the re-evaluation of renal function.

The regulatory documentation structures the interaction profile around the need to mitigate drug accumulation and monitor for combined effects, especially those related to acidosis and hypoglycemia.

Modulating Cellular Energy in the Liver

Glafornil XR's primary action begins in the liver, where it selectively accumulates via Organic Cation Transporters (OCT1). The drug acts as an inhibitor of Mitochondrial Respiratory Chain Complex I, disrupting cellular energy production. This action shifts the ratio of ATP to AMP, leading to the activation of the central energy-sensing enzyme, AMP-activated protein kinase (AMPK). This regulatory cascade subsequently reduces the rate of hepatic glucose synthesis (gluconeogenesis), which influences systemic glucose concentration in the fasting state.

---

Peripheral and Intestinal Effects

The mechanism extends to non-hepatic tissues by promoting glucose uptake and utilization in peripheral tissues, enhancing their response to insulin. In the gastrointestinal tract, the drug contributes to reduced intestinal glucose absorption and modulates the release of the hormone GLP-1. This combination of effects on hepatic output, peripheral uptake, and intestinal absorption results in an overall modulation of systemic glucose homeostasis without stimulating pancreatic insulin secretion.

Glafornil XR is an oral medication with administration protocols defined for the long-term management of Type 2 diabetes. The use of this extended-release tablet is governed by rules regarding dosage, timing, and patient-specific health parameters.

---

Official Administration Guidelines

Property	Instruction
Route and Form	Oral; the tablet must be swallowed whole and must not be cut, crushed, or chewed.
Dosing Schedule	Starting Dose (Adult): 500 mg once daily. The dose is gradually adjusted in 500 mg increments, no more often than every one to two weeks.
Maximum Daily Dose	The maximum recommended daily dose is 2,000 mg taken once daily.
Timing with Meals	Must be taken once daily with the evening meal.
Kidney Function Constraints	Use is constrained by renal function (eGFR). The medicine is not initiated if eGFR is between 30 and 45 mL/min/1.73 m^2 and must be discontinued if eGFR is below 30 mL/min/1.73 m^2.
Procedural Suspension	Therapy must be temporarily discontinued prior to or during specific surgical or iodinated contrast imaging procedures.
Missed Dose Rule	Patients are instructed not to take two doses the same day; the standard schedule should be resumed with the next dose.

---

These instructions establish a procedural structure that begins with a low starting dose and dictates a slow titration based on patient response. The protocol requires strict adherence to timing with the evening meal and mandates temporary suspension of use for specific medical procedures, ensuring the use context aligns with clinical parameters.

Research evidence / Overview of studies for Glafornil XR

The evidence base for Glafornil XR, which contains the active compound Metformin Hydrochloride, consists mainly of large-scale Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that evaluate its use in managing blood sugar. The information available describes what has been observed so far in study populations and contributes to the broader scientific evidence landscape.

---

Evidence for Glycemic Control in Type 2 Diabetes

The medication was studied for the clinical context of Type 2 diabetes mellitus. These studies primarily used short-term RCTs, often lasting between three to six months. Research examined key metabolic measurements, including Hemoglobin A1c (HbA1c) levels and day-to-day blood glucose readings. The research describes patterns in which measured shifts in HbA1c and glucose levels were observed in some studies.

---

Research Focus on Long-Term Outcomes and Durability

Research examined long-term outcomes to better understand the medication’s role over several years. Observational settings were applied in studies examining potential outcomes related to macrovascular endpoints, such as non-fatal myocardial infarction, stroke, and all-cause mortality. Data show patterns related to cardiovascular and mortality outcomes that were mixed or characterized by low certainty across systematic reviews.

Long-term outcomes are not fully established for all patient-important outcomes. The evidence quality varies across studies, and findings help contextualize what is known—and what is still uncertain—about long-term effects.

---

Study Limitations and Research Gaps

A key limitation is the heterogeneity of the research, meaning that the numerous trials varied widely in their design, duration, and the specific comparator drugs used. Follow-up durations were limited in many initial studies, restricting insight into the prevention of chronic, long-term complications. Furthermore, comparative evidence is lacking or subject to uncertainty for certain highly patient-reported outcomes, such as how the drug affects an individual's health-related quality of life.

Key Studies & References

1. Cardiovascular outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease (References long-term outcomes and durability)

Common questions about Glafornil XR (FAQ)

Q: Why do I have to take Glafornil XR with my evening meal?

Official administration instructions state that this extended-release medication is prescribed to be taken once daily with the evening meal. According to clinical pharmacology studies, taking the tablet with food increases the amount of drug absorbed into the body (systemic exposure). This timing with a meal is related to the drug's pharmacokinetic profile, which helps maintain consistent levels.

Q: Can Glafornil XR cause weight loss?

Regulatory documents, including data from clinical trials, sometimes include information regarding the effect of the drug on body weight. For example, some studies of the extended-release formulation reported measured changes in mean body weight from baseline in study participants. Any significant, unexpected changes in weight are typically discussed with a healthcare provider.

Q: What should I do with my expired Glafornil XR?

The official product information advises that disposal of unused or expired medication should be done according to local requirements. The preferred method is often an authorized drug take-back program. If a take-back option is not available, product guidelines suggest mixing the tablets with an undesirable substance, sealing the mixture, and placing it in household trash.

Q: Does this drug interact with common stomach medications like Cimetidine?

Official interaction statements identify Cimetidine as a medication that can interfere with the way the body clears Glafornil XR. This may lead to an increased accumulation of the drug in the body. This requires a careful consideration of the balance of benefits and risks by the prescriber.

Q: How long does it take for Glafornil XR to start working?

Pharmacology data indicates how quickly the drug reaches maximum levels in the body. The time required to reach the highest concentration in the blood is approximately 7 to 8 hours after a single dose. Consistent drug levels in the bloodstream, known as steady state, are generally reached within 24 to 48 hours of beginning a regular daily schedule, according to pharmacokinetic studies.

Q: What color is the Glafornil XR tablet?

The regulatory description of the product specifies the physical characteristics of the tablet. The active ingredient itself is a white to off-white compound, and the finished extended-release tablets are generally described as being white or off-white.

Q: What does the tablet look like (shape, markings)?

Official labeling details the physical appearance of the tablet, which is important for identification. The description includes the tablet's shape (such as oval or oblong) and the specific imprint codes that are pressed onto its surface, which typically vary by tablet strength.

Q: Is Glafornil XR a brand name or a generic drug?

Glafornil XR is a specific brand name for the generic compound Metformin Hydrochloride Extended-Release. The generic drug is also available under various other brand names and as a generic product in its extended-release form.

Q: Can women who are pregnant or breastfeeding take this medication?

Official documents contain a Risk Summary for use during pregnancy, stating there is insufficient data to determine a drug-associated risk, and the decision for use is based on the prescribing physician's assessment of clear need. Regarding breastfeeding, the label notes that small amounts of the drug can pass into human milk.

Storage and Disposal of Glafornil XR

Official Storage Conditions

Glafornil XR (metformin hydrochloride extended-release) must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. The tablets must be protected from moisture, light, and excessive heat.

Store the medication in its original container and keep it tightly closed. As a safety precaution, the product must always be kept out of sight and reach of children.

Disposal Instructions

Unused or expired Glafornil XR should be disposed of according to local requirements. The medication is not recommended for flushing down the toilet. The preferred method of disposal is typically an authorized drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance and sealed before being placed in household trash.